Intervacc is trading 7.5% down at SEK 1.03, with the catalyst unconfirmed.

  • The stock fell from SEK 1.15 on August 18; no company-specific announcement clearly explains the August 19 decline.
  • The Q2 2026 interim report was scheduled for August 20, with consensus revenue near 4.8 million and EPS of -0.05; available coverage does not confirm released results or a link to expectations.
  • Broader biotech sentiment was positive, so sector strength does not explain the decline.